Market Research Logo

Tinnitus - Pipeline Insight, 2019

Tinnitus - Pipeline Insight, 2019 report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tinnitus pipeline landscape is provided which includes the disease overview and Tinnitus treatment guidelines. The assessment part of the report embraces, in depth Tinnitus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tinnitus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Tinnitus Understanding
Tinnitus is term for the sensation of hearing a sound or the perception of noise or ringing in the ears in the absence of any external sound. Tinnitus isn't a condition itself but it’s a symptom of an underlying condition, such as age-related hearing loss, ear injury or a circulatory system disorder. In tinnitus, different types of sound, for example, ringing, whooshing or humming or buzzing in the ear. These can be continuous or temporary which is a debilitating condition. The tinnitus might seem like it’s in one ear or both, in the middle of the head or even be difficult to pinpoint. A common problem, tinnitus affects about 1 in 5 people. According to a national health study performed by the Centers for Disease Control and Prevention, at least 45 million Americans suffer from ringing in the ears, or tinnitus. There are two kinds of tinnitus: Subjective tinnitus: This is the most common type of tinnitus, which can be caused by ear problems in outer, middle or inner ear. It also can be caused by problems with the hearing (auditory) nerves or the part of brain that interprets nerve signals as sound (auditory pathways). This specific type can be hear the person only. Objective tinnitus: This rare type of tinnitus may be caused by a blood vessel problem, a middle ear bone condition or muscle contractions. In this variation the person along with examiner or doctor can also be able to observe the sound.

Tinnitus Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Tinnitus targeted therapeutics development with respective active and dormant or discontinued projects. Tinnitus pipeline report covers 11+ companies. Some of the key players include Otonomy (OTO 311), Auris Medical (AM-101), etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Tinnitus Analytical Perspective by DelveInsight
• In-depth Tinnitus Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
• Tinnitus Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report
• The Tinnitus report provides an overview of therapeutic pipeline activity for Tinnitus across the complete product development cycle including all clinical and non-clinical stages
• It comprises of detailed profiles of Tinnitus therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
• Detailed Tinnitus Research and Development progress and trial details, results wherever available, are also included in the pipeline study
• Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Tinnitus

Reasons to Buy
• Establish a comprehensive understanding of the current pipeline scenario across Tinnitus to formulate effective R&D strategies
• Assess challenges and opportunities that influence Tinnitus R&D
• Develop strategic initiatives by understanding the focus areas of leading companies.
• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Get in detail information of each product with updated information on each project along with key milestones
• Devise Tinnitus in licensing and out licensing strategies by identifying prospective partners with progressing projects for Tinnitus to enhance and expand business potential and scope
• Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs*Please Note:* The report will be delivered in 2 business days upon order confirmation.


1. Report Introduction
2. Tinnitus
2.1. Tinnitus Disease Overview
2.2. Tinnitus History
2.3. Tinnitus Symptoms
2.4. Tinnitus Causes
2.5. Tinnitus Pathophysiology
2.6. Tinnitus Diagnosis
2.6.1. Diagnostic Guidelines
3. Tinnitus Current Treatment Patterns
3.1. Treatment Guidelines
4. Tinnitus - DelveInsight’s Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Tinnitus companies collaborations, Licensing, Acquisition –Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Tinnitus Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Tinnitus Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono / Combination)
4.2.2.1. Assessment by Stage and Product Type
4.2.3. Assessment by Route of Administration
4.2.3.1. Assessment by Stage and Route of Administration
4.2.4. Assessment by Molecule Type
4.2.4.1. Assessment by Stage and Molecule Type
4.2.5. Assessment by MOA
4.2.5.1. Assessment by Stage and MOA
5. Tinnitus Pipeline Therapeutics
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
5.4.1. Comparative Analysis
5.5. Inactive Products
6. Tinnitus -Products Analysis
6.1. Product Profiles
6.1.1. OTO 311: Otonomy
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
6.1.2. AM-101: Auris Medical
6.1.2.1. Product Description
6.1.2.1.1. Product Overview
6.1.2.1.2. Mechanism of Action
6.1.2.2. Research and Development
6.1.2.2.1. Clinical Studies
6.1.2.2.1.1. Detailed Study Description
6.1.2.2.1.2. Study Results
6.1.2.2.1.3. Clinical Trials: Tabular View
6.1.2.3. Product Development Activities
6.1.2.3.1. Tabulated Product Summary
6.1.2.3.1.1. General Description Table
To be continued in the report
7. Recent Technologies
8. Tinnitus Key Companies
8.1. Synphora AB
8.2. Sound Pharmaceuticals
8.3. Otonomy, Inc.
8.4. Novartis Pharmaceuticals
8.5. NeuroSystec Corporation
8.6. Merz Pharmaceuticals GmbH
8.7. Korea Otsuka Pharmaceutical
8.8. GlaxoSmithKline
8.9. Bayer
8.10. Autifony Therapeutics
8.11. Auris Medical
9. Tinnitus Key Products
9.1. JB 004A
9.2. SPI-1005
9.3. OTO-313
9.4. OTO-203
9.5. BGG492A
9.6. NST-001
9.7. Neramexane mesylate
9.8. Cilostazol
9.9. Vestipitant
9.10. Levitra
9.11. AUT00063
9.12. AM-101
10. Dormant and Discontinued Products
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation
11. Tinnitus - Unmet Needs
12. Tinnitus - Future Perspectives
13. Appendix
14. Report Methodology
14.1. Secondary Research
14.2. Expert Panel Validation
Table 1. Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Tinnitus Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products
Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Tinnitus companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Tinnitus Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook